Details for Patent: 9,434,754
✉ Email this page to a colleague
Which drugs does patent 9,434,754 protect, and when does it expire?
Patent 9,434,754 protects ISTURISA and is included in one NDA.
This patent has forty-six patent family members in thirty-one countries.
Summary for Patent: 9,434,754
Title: | Use of an adrenal hormone-modifying agent |
Abstract: | The present invention relates to a method of treating a disease or disorder characterized by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): wherein n is 1 or 3; R is hydrogen or --C(O)N(R.sub.a)(R.sub.b) wherein R.sub.a and R.sub.b are independently --(C.sub.1-C.sub.4) alkyl, or --(C.sub.1-C.sub.4) alkyl-(C.sub.5-C.sub.7) aryl, wherein each of R.sub.a and R.sub.b is optionally substituted by --(C.sub.1-C.sub.4) alkoxy; R.sub.1, R.sub.2, and R.sub.3, are independently hydrogen, halogen, cyano or --(C.sub.6-C.sub.10) aryl, wherein said --(C.sub.6-C.sub.10) aryl is optionally substituted by halogen, with the proviso that no more than one of R.sub.1, R.sub.2, and R.sub.3 is hydrogen; and R.sub.4 and R.sub.5 are hydrogen; or a pharmaceutically acceptable salt thereof. ##STR00001## |
Inventor(s): | Hu; Qi-Ying (Needham, MA), Ksander; Gary Michael (Amherst, MA), Meredith; Erik (Hudson, MA), Monovich; Lauren G (Belmont, MA), Papillon; Julien (Somerville, MA), Schumacher; Christoph (Bettingen, CH) |
Assignee: | Novartis AG (Basel, CH) |
Application Number: | 14/079,018 |
Patent Claim Types: see list of patent claims | Compound; |
Patent landscape, scope, and claims: | More… ↓ |
Drugs Protected by US Patent 9,434,754
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Recordati Rare | ISTURISA | osilodrostat phosphate | TABLET;ORAL | 212801-001 | Mar 6, 2020 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
Recordati Rare | ISTURISA | osilodrostat phosphate | TABLET;ORAL | 212801-002 | Mar 6, 2020 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
Recordati Rare | ISTURISA | osilodrostat phosphate | TABLET;ORAL | 212801-003 | Mar 6, 2020 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,434,754
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
European Patent Office | 2523731 | ⤷ Subscribe | 301043 | Netherlands | ⤷ Subscribe |
European Patent Office | 2523731 | ⤷ Subscribe | CA 2020 00025 | Denmark | ⤷ Subscribe |
European Patent Office | 2523731 | ⤷ Subscribe | 132020000000052 | Italy | ⤷ Subscribe |
European Patent Office | 2523731 | ⤷ Subscribe | 122020000026 | Germany | ⤷ Subscribe |
European Patent Office | 2523731 | ⤷ Subscribe | LUC00159 | Luxembourg | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |